Free Trial
NASDAQ:HOWL

Werewolf Therapeutics Q4 2024 Earnings Report

Werewolf Therapeutics logo
$1.22 +0.03 (+2.52%)
Closing price 04:00 PM Eastern
Extended Trading
$1.23 +0.01 (+0.41%)
As of 05:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Werewolf Therapeutics EPS Results

Actual EPS
-$0.46
Consensus EPS
-$0.43
Beat/Miss
Missed by -$0.03
One Year Ago EPS
N/A

Werewolf Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$1.00 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Werewolf Therapeutics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Tuesday, March 11, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Werewolf Therapeutics' Q2 2025 earnings is scheduled for Thursday, August 14, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 11:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Werewolf Therapeutics Earnings Headlines

Trump’s Bitcoin Reserve is No Accident…
For the first time in history, we have a president who understands crypto's potential to bypass the banking system entirely. And Wall Street's biggest players know it. I've created a blueprint revealing how everyday investors can turn this historic shift into potentially life-changing wealth. Like the 75,000 new millionaires created in the last bull run— only this time with institutional backing.
See More Werewolf Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Werewolf Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Werewolf Therapeutics and other key companies, straight to your email.

About Werewolf Therapeutics

Werewolf Therapeutics (NASDAQ:HOWL), a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

View Werewolf Therapeutics Profile

More Earnings Resources from MarketBeat